Images List Premium Download Classic

Fatty Liver

Fatty Liver-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Compositions and methods for treating diabetes and liver diseases
Cempra Pharmaceuticals, Inc.
June 15, 2017 - N°20170165286

Compounds, compositions, and methods are described herein for treating diabetes, fatty liver diseases, fibrotic diseases, such as liver and pulmonary fibrosis, and hepatocellular carcinoma.
Inhibitors of the farnesoid x receptor and uses in medicine
The Penn State Research Foundation
June 01, 2017 - N°20170152283

Disclosed are inhibitors of the farnesoid x receptor, for example of formula (i), wherein r1, r2, r4, x, y, z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier ...
Systems and methods for detecting a fatty liver from a computed tomography (ct) scan
The Penn State Research Foundation
May 25, 2017 - N°20170148156

There is provided a computer-implemented method for detecting a fatty liver, comprising: receiving imaging data of a computed tomography (ct) scan performed using a single source ct scanner with settings selected for imaging of non-fatty-liver pathology, segmenting a region of the liver by creating a binary image by applying binary segmentation to a sub-set of pixels of the imaging data ...
Fatty Liver Patent Pack
Download + patent application PDFs
Fatty Liver Patent Applications
Download + Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pharmaceutical compositions of berberine with epa and dha, and methods thereof
Shenzhen Hightide Biopharmaceutical, Ltd.
May 18, 2017 - N°20170135995

The invention provides various novel compositions of berberine in combination with pharmacologically active epa and dha, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, ...
Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
Genfit
May 11, 2017 - N°20170128399

The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of general formula (i) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, ...
7-hydroxy cannabidiol (7-oh-cbd) for use in the treatment of non-alcoholic fatty liver disease (nafld)
Gw Pharma Limited
May 11, 2017 - N°20170128385

The liver plays a key role in regulating total body energy homeostasis and its ability to do so is greatly affected by the occurrence of pathological conditions such as hepatosteatosis or non-alcoholic fatty liver disease (nafld), which contributes to hepatic insulin resistance and potentially end-stage liver disease-related mortality. Triglyceride accumulation in hepatocytes of steatotic livers results from the incorporation of ...
Fatty Liver Patent Pack
Download + patent application PDFs
Fatty Liver Patent Applications
Download + Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Engineered polypeptides having enhanced duration of action
Astrazeneca Pharmaceuticals Lp
April 27, 2017 - N°20170114114

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, ...
Thyromimetics for the treatment of fatty liver diseases
Metabasis Therapeutics, Inc.
April 27, 2017 - N°20170112864

The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
Composition for preventing and treating non-alcoholic fatty liver diseases
Jbk Natural Medicine Institute
April 20, 2017 - N°20170106035

A composition includes a black chokeberry extract and at least one of a thistle extract, a black hoof mushroom extract and a mixture thereof. The composition is effective in preventing and treating non-alcoholic fatty liver disease caused by accumulation of fat in the liver due to excessive intake of nutrients or metabolic syndrome regardless of alcohol intake. The composition can ...
Method and system for treating non-alcoholic fatty liver disease
Jbk Natural Medicine Institute
April 20, 2017 - N°20170106026

A method and system for treating non-alcoholic fatty liver disease (nafld) involves the modulation of the gut microbial of a person suffering from nafld, and in particular the provision of a probiotic therapy configured to reduce liver aminotransferases, total-cholesterol, tnf-α and to improve insulin resistance in nafld patients.
Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
Hadasit Medical Research Services And Development Ltd.
April 20, 2017 - N°20170105996

Methods of treating patients suffering from non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), including those also suffering front type ii diabetes mellitus (t2dm), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.
Novel composition for nonalcoholic fatty liver disease (nafld)
Cadila Healthcare Limited
March 30, 2017 - N°20170087127

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (...
Pharmaceutical composition for controlling blood lipids and body weight, and use thereof
Beijing Hebabiz Management Co., Ltd.
March 23, 2017 - N°20170080043

The invention provides a traditional chinese medicine composition for the control of blood lipids and/or weight of body, which includes poria and paeoniae radix alba, etc. The traditional chinese medicine composition can be applied in reducing the total cholesterol level, triacylglycerol level, and low density lipoprotein cholesterol level in the body; increasing body high density lipoprotein cholesterol level, reducing ...
Fatty Liver Patent Pack
Download + patent application PDFs
Fatty Liver Patent Applications
Download + Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
Novartis Ag
March 09, 2017 - N°20170065678

The invention relates to the identification of new therapeutic methods for the fgf21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e. G. Insulin receptor mutation disorders (insr disorders) and/or autoimmune insulin receptor disorders (type b insulin resistance)), defects in insulin production such as type 1 diabetes mellitus, ...
Crystallized xylose isomerase in prevention of the development of non-alcoholic fatty liver disease
Sciotec Diagnostic Technologies Gmbh
March 02, 2017 - N°20170056485

The present invention relates to the composition comprising crystalline xylose-isomerase and at least one salt of a metal and/or alkaline earth metal for the treatment and prevention of non-alcoholic fatty liver disease and other fructose-related disorders.
Methods for treating metabolic disorders using fgf
Salk Institute For Biological Studies
March 02, 2017 - N°20170056475

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.
Mitochondrial-derived peptide mots3 regulates metabolism and cell survival
The Regents Of The University Of California
February 23, 2017 - N°20170049853

Mots3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using mots3 and pharmaceutical compositions thereof are disclosed herein.
Pharmaceutical composition containing gpr119 ligand as active ingredient for preventing or treating non-alcoholic fatty liver ...
Snu R&db Foundation
February 23, 2017 - N°20170049773

The present invention relates to a pharmaceutical composition containing a g protein coupled receptor 119 (gpr119) ligand as an active ingredient for preventing or treating non-alcoholic fatty liver disease. More particularly, it was confirmed that the gpr119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways ...
Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated ...
Vanderbilt University
February 16, 2017 - N°20170042964

The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject. Compositions and methods including a nuclear transport modifier may ...
Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
Shenzhen Hightide Biopharmaceutical, Ltd.
February 09, 2017 - N°20170037043

The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their ...
Composition for preventing or treating fatty liver diseases
Lg Life Sciences Ltd.
February 09, 2017 - N°20170035776

The present invention relates to a pharmaceutical composition for preventing or treating fatty liver diseases, containing (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1h-indol-7-yl]amine or a pharmaceutically acceptable salt thereof as active ingredients. (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1h-indol-7-yl]amine or a pharmaceutically acceptable salt thereof, according to the present invention, can effectively ...
Loading